Tolerating False Positives: Amylyx, FDA, And The Legal Case For Broad Regulatory Flexibility

person stretching while working on desk
Regulatory flexibility was a central theme at Amylyx’s second-chance FDA advisory panel for its ALS drug. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers